IGF2BP2 Enhances Anti-Angiogenic CRC Therapy | AcademicJobs CN
Discover how SYSU researchers identified IGF2BP2-CEMIP axis to boost anti-angiogenic therapies for colorectal cancer, addressing China's rising CRC burden.
No reviews yet. Be the first to rate Jun!
Jun Yu holds an honorary position as Dean of the Precision Medicine Research Institute at the First Affiliated Hospital of Sun Yat-sen University. He is also Choh-Ming Li Professor of Medicine and Therapeutics at The Chinese University of Hong Kong, where he serves as Assistant Dean of the Faculty of Medicine and Director of the State Key Laboratory of Digestive Disease.
His work focuses on digestive diseases and precision medicine, with collaborations on research involving tumor organoids, liver cancer, and related clinical studies published in peer-reviewed journals.
Professional Email: null
Discover how SYSU researchers identified IGF2BP2-CEMIP axis to boost anti-angiogenic therapies for colorectal cancer, addressing China's rising CRC burden.